Masuno T, Ikeda T, Yokota S, Komuta K, Ogura T, Kishimoto S
Cancer Res. 1986 Aug;46(8):4195-9.
The present study was performed to elucidate the differences in immune status between patients with small cell lung cancer (SCLC) and those with non-small cell lung cancer. The study group consisted of 18 patients with SCLC and 15 with non-SCLC. Two healthy volunteers and 13 patients with benign disease were also included in the present study as the non-cancer control. In the non-SCLC group, although not statistically significant, the percentages of both OKT3+ and OKT4+ T-lymphocytes in the peripheral blood lymphocytes (PBL) were slightly decreased, associated with a slight increase in the percentage of OKT8+ T-cells, and a slight decrease in the OKT4+ to OKT8+ T-cell ratio. In contrast, the PBL of the SCLC patients showed significantly lower proliferative responses to phytohemagglutinin and human recombinant interleukin 2 than did the PBL of both the SCLC patients and the noncancer control group. The ability of PBL to produce lymphokines (interleukin 2 and macrophage activating factor) was significantly impaired in the SCLC group but not in the non-SCLC group. These results suggest that suppression of helper T-cell functions and/or potentiation of suppressor T-cell functions should occur in patients with SCLC.
本研究旨在阐明小细胞肺癌（SCLC）患者与非小细胞肺癌患者免疫状态的差异。研究组包括18例SCLC患者和15例非SCLC患者。本研究还纳入了2名健康志愿者和13例良性疾病患者作为非癌症对照。在非SCLC组中，外周血淋巴细胞（PBL）中OKT3 +和OKT4 + T淋巴细胞的百分比虽无统计学意义，但略有下降，同时OKT8 + T细胞百分比略有增加，OKT4 +与OKT8 + T细胞比值略有下降。相比之下，SCLC患者的PBL对植物血凝素和人重组白细胞介素2的增殖反应明显低于SCLC患者和非癌症对照组。SCLC组PBL产生淋巴因子（白细胞介素2和巨噬细胞活化因子）的能力明显受损，而非SCLC组则未受损。这些结果表明，SCLC患者应存在辅助性T细胞功能抑制和/或抑制性T细胞功能增强。
